Mosapride citrate, a 5-HT4 receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men

Endocrine Journal

Volumn 60, Issue 4, 2013, Pages 493-499

  Aoki, Kazutaka ^a   Kamiyama, Hiroshi ^a   Masuda, Kiyomi ^a   Togashi, Yu ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Glucagon Like peptide 1 (GLP 1); Glucose Dependent insulinotropic polypeptide (GIP); Mosapride citrate

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; MOSAPRIDE;

ADULT; ANTIDIABETIC ACTIVITY; ARTICLE; CASE REPORT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; MORNING DOSAGE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

ADULT; BENZAMIDES; BLOOD GLUCOSE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRACT; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; MORPHOLINES; POSTPRANDIAL PERIOD; SEROTONIN 5-HT4 RECEPTOR AGONISTS; UP-REGULATION;

EID: 84876966962     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4: 329-335.
2. Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, et al. (2012) Comparisons of the effects of 12-weekadministration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 14: 283-287.
3. Aoki K, Miyazaki T, Nagakura J, Orime K, Togashi Y, et al. (2010) Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1and glucose dependent insulinotropic polypeptide levels in healthy men. Endocr J 57: 673-677.
4. Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y (2010) Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57: 667-672.
5. Masuda K, Aoki K, Terauchi Y (2011) Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance (NGT), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). J Diabetes Invest 2: 435-440.
6. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, et al. (2012) Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 49: 225-230.
7. Sakurai-Yamashita Y, Takada K, Takemura K, Yamashita K, Enjoji A, et al. (1999) Ability of mosapride to bind to 5-HT4 receptor in the human stomach. Jpn J Pharmacol 79: 493-496.
8. McLean PG, Coupar IM (1996) Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors. Br J Pharmacol 117: 238-239.
9. Sakurai-Yamashita Y, Yamashita K, Yoshimura M, Taniyama K (2000) Differential localization of 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors in the human rectum. Life Sci 66: 31-34.
10. Gershon MD (2004) Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther Suppl 7: 3-14.
11. Yoshida N, Omoya H, Kato S, Ito T (1993) Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 43: 1078-1083.
12. Ueno N, Inui A, Asakawa A, Takao F, Komatsu Y, et al. (2002) Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus. Diabetologia 45: 792-797.
13. Koshiyama H, Shimono D, Wada Y, Nakamura Y (2000) Improvement of glycemic control after treatment with mosapride for diabetic gastropathy. Diabetes Care 23: 1198-1199.
14. Braden B, Enghofer M, Schaub M, Usadel KH, Caspary WF, et al. (2002) Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 16: 1341-1346.
15. Stacher G, Schernthaner G, Francesconi M, Kopp HP, Bergmann H, et al. (1999) Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: a double blind cross-over trial. J Clin Endocrinol Metab 84: 2357-2362.
16. Kuo P, Bellon M, Wishart J, Smout AJ, Holloway RH, et al. (2010) Effects of metoclopramide on duodenalmotility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. Am J Physiol Gastrointest Liver Physiol 299: G1326-1333.
17. Masuda K, Aoki K, Terauchi Y (2012) Comparison of plasma active glucagon-like peptide-1 (GLP-1) levels assayed with or without plasma extraction in non-diabetic men. Endocr J 59: 435-438.
18. Nam JS, Nam JY, Yoo JS, Cho M, Park JS, et al. (2010) The effect of mosapride (5HT-4 receptor agonist) on insulin sensitivity and GLUT4 translocation. Diabetes Res Clin Pract 87: 329-334.
19. Ueno N, Satoh Y (2009) Rapid effect of mosapride citrate, 5-HT4 receptor agonist, on fasting blood glucose in Type 2 diabetes patients. J Diabetes Complications 23: 255-256.
20. Romero F, Nicolau J, Flores L, Casamitjana R, Ibarzabal A, et al. (2012) Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc 26: 2231-2239.
21. Gebhard B, Holst JJ, Biegelmayer C, Miholic J (2001) Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome. Dig Dis Sci 46:1915-1923.
22. Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, et al. (2007) Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117: 246-257.
23. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, et al. (1984) Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26: 44-49.
24. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, et al. (2003) Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets. Endocrinology 144: 5149-5158.
25. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, et al.; NN8022-1807 Study Group (2009) Effects of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study. Lancet 374: 1606-1616.
26. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, et al. (2010) Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33: 1173-1175.
27. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR (2010) The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 57: 359-372.
28. Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, et al. (2012) The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr J 59: 889-894.